The rise of mucormycosis in Covid-19 patients in India

被引：15
作者：
Bhatia, Migresh [1 ]
机构：
[1] London Sch Econ, Dept Hlth Policy, London, England
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2022年 / 20卷 / 02期
关键词：
D O I：
10.1080/14787210.2021.1960822
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：137 / 138
页数：2
相关论文
共 12 条
[1]  
[Anonymous], 2021, Times of India
[2]  
[Anonymous], 2021, The Economic Times
[3]  
[Anonymous], 2021, INDIA TODAY
[4]  
Bhat I., 2021, J BACTERIOL MYCOL OP, V9, P69, DOI DOI 10.15406/JBMOA.2021.09.00298
[5]  
India State-Level Disease Burden Initiative Diabetes Collaborators, 2018, LANCET, V6
[6]  
O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI [10.1086/344188, 10.1086/502007]
[7]  
Oxygen Press Trust of India, HINDU
[8]  
Runwal P., 2021, RARE BLACK FUNGUS IS
[9]   Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India [J].
Singh, Awadhesh Kumar ;
Singh, Ritu ;
Joshi, Shashank R. ;
Misra, Anoop .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (04)
[10]  
Statista, 2019, COUNTR HIGH NUMB DIA
12